Table 2.
Results—items that reached consensus.
| Item | Median (IQR) | Round of Consensus | Agreement, % (n/N) |
|---|---|---|---|
| 1.2 30-day survival | 4 (3–5) | 1 | 75.0 (21/28) |
| 1.3 90-day survival (no mortality for all causes) | 3.5 (3–5) | 1 | 75.0 (21/28) |
| 2.2 Negative margins | 4 (3–5) | 1 | 85.7 (24/28) |
| 2.3 ≥12 LNs harvested | 4 (3–4.25) | 1 | 78.6 (22/28) |
| 2.5 Negative margins + 12 LNs | 4 (3–5) | 1 | 75.0 (21/28) |
| 2.7 Negative margins + 12 LNs + 5 cm for colon | 4 (3–5) | 1 | 85.7 (24/28) |
| 3.1 Ostomy fashioning | 4 (3–5) | 2 | 92.6 (25/27) |
| 3.2 Minimally invasive approach | 4 (3–5) | 1 | 89.3 (25/28) |
| 4.1 No reinterventions | 4 (3–5) | 1 | 82.1 (23/28) |
| 4.2 No complications | 4 (3–5) | 1 | 78.6 (22/28) |
| 4.6 No readmission (30 days) | 4 (3–5) | 1 | 85.7 (24/28) |
| 4.8 ERAS, at least 10 items | 4 (3–5) | 1 | 75.0 (21/28) |
| 4.9 ERAS, according to comorbidities of the patient | 3 (2.75–5) | 1 | 75.0 (21/28) |
| 4.9 Clavien–Dindo grade < 3b | 4 (4–5) | 2 | 88.9 (24/27) |
| 5.1 Appropriate CHT and RT regimens | 3 (2.75–4) | 1 | 75.0 (21/28) |
| 5.2 CHT and RT for rectal cancer | 4 (4–5) | 1 | 92.9 (26/28) |
| 5.3 Complete colonoscopy after or before surgery | 4.5 (2.75–5) | 1 | 75.0 (21/28) |
| 5.4 Tumor Board Evaluation | 5 (4–5) | 1 | 96.4 (21/28) |
IQR: interquartile range; LN: lymph node; ERAS: Enhanced Recovery After Surgery; CHT: chemotherapy; RT: radiotherapy; n: number of agree responses; N: total responses.